Bausch Health's Securities Litigation Casts Shadow Over B+L's Future As Independent Firm
Executive Summary
For all B+L has going for it, including consumer health eye health and vision care products as its sales driver, it could be stymied by investors alleging Bausch Health conducted fraudulent conveyance by spinning out B+L through an IPO in 2022.
You may also be interested in...
J&J Has Kenvue IPO Roadshow In One Lane, Potentially Long Road For Talc Litigation In Other
Roadshow stated for IPO planned for before end of 2023 of 151.2m shares of Kenvue common stock currently expected at between $20 and $23 per share. Analysts positive on IPO but caution launch wouldn’t come problem-free.
Consumer Products Drive B+L Sales As Spinout Expenses, Increasing Costs Drag Results
Consumer health products account for majority of vision care sales during Q4 and all 2022, with launch of Lumify eye drops in Canada a key driver. “While consumers have faced pressure from higher inflation and potential economic uncertainty, we have not seen broad, fundamental changes in the segment,” says CFO Sam Eldessouky.
Lumify Reaches Canada As Consumer Health Leads Sales In Bausch + Lomb's Debut Quarter
Lumify sales grew reported 21% to brand-record $35m in Q2, Bausch + Lomb’s first quarter since separating from Bausch Health through an IPO in May.